[1]
|
中国心血管健康与疾病报告编写委员会. 中国心血管健康与疾病报告2022概要[J]. 心脑血管病防治, 2023, 23(7): 1-19 24.
|
[2]
|
中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中国循环杂志, 2023, 38(3): 237-271.
|
[3]
|
国家卫生健康委员会. 中国居民营养与慢性病状况报告(2020年) [J]. 营养学报, 2020, 42(6): 521.
|
[4]
|
Estruch, R. (2010) Anti-Inflammatory Effects of the Mediterranean Diet: The Experience of the PREDIMED Study. Proceedings of the Nutrition Society, 69, 333-340. https://doi.org/10.1017/S0029665110001539
|
[5]
|
Wang, Y., Feng, L., Zeng, G., et al. (2022) Effects of Cuisine-Based Chinese Heart-Healthy Diet in Lowering Blood Pressure among Adults in China: Multicenter, Single-Blind, Randomized, Parallel Controlled Feeding Trial. Circulation, 146, 303-315. https://doi.org/10.1161/CIRCULATIONAHA.122.059045
|
[6]
|
Oktay, A.A., Lavie, C.J., Kokkinos, P.F., et al. (2017) The Interaction of Cardiorespiratory Fitness with Obesity and the Obesity Paradox in Cardiovascular Disease. Progress in Cardiovascular Diseases, 60, 30-44. https://doi.org/10.1016/j.pcad.2017.05.005
|
[7]
|
Fiuza-Luces, C., Santos-Lozano, A., Joyner, M., et al. (2018) Exercise Benefits in Cardiovascular Disease: Beyond Attenuation of Traditional Risk Factors. Nature Reviews Cardiology, 15, 731-743. https://doi.org/10.1038/s41569-018-0065-1
|
[8]
|
Melov, S., Tarnopolsky, M.A., Beckman, K., et al. (2007) Resistance Exercise Reverses Aging in Human Skeletal Muscle. PLOS ONE, 2, e465. https://doi.org/10.1371/journal.pone.0000465
|
[9]
|
Young, D.R., Hivert, M.-F., Alhassan, S., et al. (2016) Sedentary Behavior and Cardiovascular Morbidity and Mortality: A Science Advisory from the American Heart Association. Circulation, 134, e262-e279. https://doi.org/10.1161/CIR.0000000000000440
|
[10]
|
Baigent, C., Blackwell, L., Emberson, J., et al. (2010) Efficacy and Safety of More Intensive Lowering of LDL Cholesterol: A Meta-Analysis of Data from 170,000 Participants in 26 Randomised Trials. The Lancet, 376, 1670-1681. https://doi.org/10.1016/S0140-6736(10)61350-5
|
[11]
|
Ridker, P.M., Mora, S. and Rose, L. (2016) Percent Reduction in LDL Cholesterol Following High-Intensity Statin Therapy: Potential Implications for Guidelines and for the Prescription of Emerging Lipid-Lowering Agents. European Heart Journal, 37, 1373-1379. https://doi.org/10.1093/eurheartj/ehw046
|
[12]
|
血脂康调整血脂对冠心病二级预防研究协作组. 中国冠心病二级预防研究[J]. 中华心血管病杂志, 2005, 33(2): 109-115.
|
[13]
|
Liao, J., Wang, X., Li, Z. and Ouyang, D. (2021) Pharmacokinetic Study of Oral 14C-Radiolabeled Hyzetimibe, a New Cholesterol Absorption Inhibitor. Frontiers in Pharmacology, 12, Article 665372. https://doi.org/10.3389/fphar.2021.665372
|
[14]
|
韩雅玲, 马颖艳, 苏国海, 等. 阿利西尤单抗与依折麦布治疗高胆固醇血症合并心血管高危患者的疗效及安全性比较: ODYSSEY EAST研究中国地区亚组分析[J]. 中华心血管病杂志, 2020, 48(7): 593-599.
|
[15]
|
Thedrez, A., Blom, D.J., Ramin-Mangata, S., et al. (2018) Homozygous Familial Hypercholesterolemia Patients with Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Arteriosclerosis, Thrombosis, and Vascular Biology, 38, 592-598. https://doi.org/10.1161/ATVBAHA.117.310217
|
[16]
|
Chen, Y., Yuan, Z., Lu, J., et al. (2019) Randomized Study of Evolocumab in Patients with Type 2 Diabetes and Dyslipidaemia on Background Statin: Pre-Specified Analysis of the Chinese Population from the BERSON Clinical Trial. Diabetes, Obesity and Metabolism, 21, 1464-1473. https://doi.org/10.1111/dom.13700
|
[17]
|
国家老年医学中心, 中国医药教育协会老年药学专业委员会, 中国药学会医院药学专业委员会, 等. 小干扰RNA降脂药物药学专家共识[J]. 中国医院药学杂志, 2024, 44(1): 9-17.
|
[18]
|
Ray, K.K., Bays, H.E., Catapano, A.L., et al. (2019) Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. The New England Journal of Medicine, 380, 1022-1032. https://doi.org/10.1056/NEJMoa1803917
|
[19]
|
Nissen, S.E., Lincoff, A.M., Brennan, D., et al. (2023) Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. The New England Journal of Medicine, 388, 1353-1364. https://doi.org/10.1056/NEJMoa2215024
|
[20]
|
Raal, F.J., Rosenson, R.S., Reeskamp, L.F., et al. (2020) Evinacumab for Homozygous Familial Hypercholesterolemia. The New England Journal of Medicine, 383, 711-720. https://doi.org/10.1056/NEJMoa2004215
|
[21]
|
Markham, A. (2021) Evinacumab: First Approval. Drugs, 81, 1101-1105. https://doi.org/10.1007/s40265-021-01516-y
|
[22]
|
Rosenson, R.S., Burgess, L.J., Ebenbichler, C.F., et al. (2020) Evinacumab in Patients with Refractory Hypercholesterolemia. The New England Journal of Medicine, 383, 2307-2319. https://doi.org/10.1056/NEJMoa2031049
|
[23]
|
Hamada, M. and Farzam, K. (2024) Mipomersen. StatPearls, Treasure Island.
|
[24]
|
Laufs, U., Parhofer, K.G., Ginsberg, H.N., et al. (2020) Clinical Review on Triglycerides. European Heart Journal, 41, 99-109. https://doi.org/10.1093/eurheartj/ehz785
|
[25]
|
Zomer, E., Gurusamy, K., Leach, R., et al. (2016) Interventions that Cause Weight Loss and the Impact on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis. Obesity Reviews, 17, 1001-1011. https://doi.org/10.1111/obr.12433
|
[26]
|
Appel, L.J., Sacks, F.M., Carey, V.J., et al. (2005) Effects of Protein, Monounsaturated Fat, and Carbohydrate Intake on Blood Pressure and Serum Lipids: Results of the OmniHeart Randomized Trial. JAMA, 294, 2455-2464. https://doi.org/10.1001/jama.294.19.2455
|
[27]
|
Boden, W.E., Probstfield, J.L., Anderson, T., et al. (2011) Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy. The New England Journal of Medicine, 365, 2255-2267. https://doi.org/10.1056/NEJMoa1107579
|
[28]
|
Katsiki, N., Nikolic, D., Montalto, G., et al. (2013) The Role of Fibrate Treatment in Dyslipidemia: An Overview. Current Pharmaceutical Design, 19, 3124-3131. https://doi.org/10.2174/1381612811319170020
|
[29]
|
Manson, J.E., Cook, N.R., Lee, I.-M., et al. (2019) Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer. The New England Journal of Medicine, 380, 23-32. https://doi.org/10.1056/NEJMoa1811403
|
[30]
|
Yokoyama, M., Origasa, H., Matsuzaki, M., et al. (2007) Effects of Eicosapentaenoic Acid on Major Coronary Events in Hypercholesterolaemic Patients (JELIS): A Randomised Open-Label, Blinded Endpoint Analysis. The Lancet, 369, 1090-1098. https://doi.org/10.1016/S0140-6736(07)60527-3
|
[31]
|
Bhatt, D.L., Steg, P.G., Miller, M., et al. (2019) Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. The New England Journal of Medicine, 380, 11-22. https://doi.org/10.1056/NEJMoa1812792
|
[32]
|
Araki, E., Yamashita, S., Arai, H., et al. (2018) Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients with Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial. Diabetes Care, 41, 538-546. https://doi.org/10.2337/dc17-1589
|
[33]
|
Brahm, A.J. and Hegele, R.A. (2016) Lomitapide for the Treatment of Hypertriglyceridemia. Expert Opinion on Investigational Drugs, 25, 1457-1463. https://doi.org/10.1080/13543784.2016.1254187
|
[34]
|
Sacks, F.M., Stanesa, M. and Hegele, R.A. (2014) Severe Hypertriglyceridemia with Pancreatitis: Thirteen Years’ Treatment with Lomitapide. JAMA Internal Medicine, 174, 443-447. https://doi.org/10.1001/jamainternmed.2013.13309
|
[35]
|
Qamar, A., Libby, P. and Bhatt, D.L. (2019) Targeting RNA to Lower Triglycerides: Long Strides from Short Molecules. European Heart Journal, 40, 2797-2800. https://doi.org/10.1093/eurheartj/ehz321
|
[36]
|
Arca, M., Hsieh, A., Soran, H., et al. (2018) The Effect of Volanesorsen Treatment on the Burden Associated with Familial Chylomicronemia Syndrome: The Results of the ReFOCUS Study. Expert Review of Cardiovascular Therapy, 16, 537-546. https://doi.org/10.1080/14779072.2018.1487290
|
[37]
|
Witztum, J.L., Gaudet, D., Freedman, S.D., et al. (2019) Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. The New England Journal of Medicine, 381, 531-542. https://doi.org/10.1056/NEJMoa1715944
|
[38]
|
Li, J.-J., Ma, C.-S., Zhao, D., et al. (2022) Lipoprotein(a) and Cardiovascular Disease in Chinese Population: A Beijing Heart Society Expert Scientific Statement. JACC: Asia, 2, 653-665. https://doi.org/10.1016/j.jacasi.2022.08.015
|
[39]
|
Tsimikas, S. (2017) A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. Journal of the American College of Cardiology, 69, 692-711. https://doi.org/10.1016/j.jacc.2016.11.042
|
[40]
|
Yeang, C., Karwatowska-Prokopczuk, E., Su, F., et al. (2022) Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. Journal of the American College of Cardiology, 79, 1035-1046. https://doi.org/10.1016/j.jacc.2021.12.032
|